Faron Pharmaceuticals Oy Sustainability Reports
Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies. Its lead clinical drug asset is bexmarilimab, a novel macrophage-guiding antibody targeted at overcoming treatment resistance in hematological malignancies and solid tumors.
Sector: Manufacturing
Country: Finland
Exchange: London Stock Exchange (AIM)
LEI: 7437009H31TO1DC0EB42
FIGI: BBG008R5TCG6
12 reports from 2015 to 2025
